GlassScriptPhysician profile
Nosayaba Enofe
NPI 1225424013
$7,810.60
in general payments reported to CMS, 2019-2025
9 companies · $5,511 in 2025
The $5,511 reported for 2025 was more than what 91% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.03 · 2020: $44.80 · 2021: $116 · 2022: $156 · 2023: $941 · 2024: $1,029 · 2025: $5,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,076 · Food and Beverage: $1,404 · Education: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,076.06 |
| Food and Beverage | $1,403.70 |
| Education | $1,001.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $2,453.18 | 2023-2025 | Synergy Ablation System, Epi-Sense Guided Coagulation System With Visitrax, Atricure Cryoice Cryoablation System (Cryo2) |
| Edwards Lifesciences Corporation | $2,000.63 | 2025 | Sapien 3 Ultra Resilia |
| Abiomed | $1,754.82 | 2025 | |
| Intuitive Surgical, INC. | $1,028.98 | 2024 | |
| Boston Scientific Corporation | $197.70 | 2019-2022 | |
| Abbott Laboratories | $137.57 | 2025 | Navitor |
| Medtronic, INC. | $115.76 | 2021 | |
| Paladin Technology Solutions | $105.58 | 2025 | |
| Kci USA, INC. | $16.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nosayaba Enofe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.